" class="no-js "lang="en-US"> BeiGene - Medtech Alert
Wednesday, August 13, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
BeiGene | Pharmtech Focus

BeiGene

About BeiGene

BeiGene

BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235) is a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide. With a broad portfolio of more than 40 clinical candidates, we are expediting development of our diverse pipeline of novel therapeutics through our own capabilities and collaborations. BeiGene has a growing global team of more than 8,000 colleagues across five continents. We have headquarters located in Cambridge, Mass., Basel and Beijing.

Related Story

Drug Development

 BeiGene Receives New Approvals for BRUKINSA (zanubrutinib) in China | MTA

BeiGene Receives New Approvals for BRUKINSA (zanubrutinib) in China

May 8 2023

BeiGene, a global biotechnology company, has announced the China National Medical Products Administration (NMPA) approved […]

News

 MapKure, BeiGene and SpringWorks Present Clinical Data on BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors | MTA

MapKure, BeiGene and SpringWorks Present Clinical Data on BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors

April 18 2023

MapKure, BeiGene and SpringWorks Therapeutics, today announced that they will present updated clinical data from the […]

News

 BeiGene Enters New Phase to Expand US Manufacturing and R&D Footprint in New Jersey | MTA

BeiGene Enters New Phase to Expand US Manufacturing and R&D Footprint in New Jersey

March 21 2023

BeiGene, a global biotechnology company, announced today that the last piece of structural steel will […]

News

 Leap Therapeutics Provides Update on BeiGene Option Agreement for DKN-01 | MTA

Leap Therapeutics Provides Update on BeiGene Option Agreement for DKN-01

March 17 2023

Leap Therapeutics, a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that […]

Drug Development

 BRUKINSA Approved in the U.S. for Chronic Lymphocytic Leukemia | PTF

BRUKINSA Approved in the U.S. for Chronic Lymphocytic Leukemia

January 20 2023

BeiGene, a global biotechnology company, today announced that the United States Food and Drug Administration […]

Clinical Trials

 Phanes Therapeutics Announces Clinical Supply Agreement with BeiGene to Evaluate PT199 in Combination with Tislelizumab | PTF

Phanes Therapeutics Announces Clinical Supply Agreement with BeiGene to Evaluate PT199 in Combination with Tislelizumab

December 9 2022

Phanes Therapeutics, a clinical-stage biotech company focused on innovative drug discovery and development in oncology, […]

Clinical Trials

 Antengene Announces Clinical Trial Collaboration with BeiGene to Evaluate Selinexor in Combination with Tislelizumab in T and NK-Cell Lymphoma | Pharmtech Focus

Antengene Announces Clinical Trial Collaboration with BeiGene to Evaluate Selinexor in Combination with Tislelizumab in T and NK-Cell Lymphoma

June 27 2022

Antengene Corporation Limited (“Antengene“ SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, […]